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geography (distance from home to hospital), and 
even hospital administrative factors (prioritiza-
tion of patients in a crowded ward). Possible 
varying practice among hospitals is unlikely to 
have influenced the main results, because we 
found no significant hospital–treatment inter-
action.
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Antithrombotic Therapy and Invasive Procedures
To the Editor: Baron et al. (May 30 issue)1 make 
important suggestions in their review article; 
however, we propose that quantitative assess-
ment of iatrogenic bleeding hazards must be 
considered as well as thrombosis prevention.1 Al-
though CHA2DS2–VASc scoring for atrial fibrilla-
tion is mentioned, the Hypertension, Abnormal 
Renal/Liver Function, Stroke, Bleeding History or 
Predisposition, Labile INR, Elderly, Drugs/Alco-
hol Concomitantly (HAS-BLED) score for bleed-
ing has also been validated.2 Both scores calcu-
late estimated annual risks and benefits and 
hence can guide future therapy.
Among the diverse causes of major bleeding 
outcomes associated with antithrombotic agents 
are periprocedural, intracranial, and gastrointes-
tinal causes.3 Although few therapies can treat 
and prevent the first two factors, data from a 
large, randomized trial show that proton-pump 
inhibitors are safe for concomitant use with anti-
thrombotic agents.4 Given the shorter time frame 
in which medications are being withheld for 
procedures, the absolute thrombotic or bleeding 
risks can be overstated; however, bleeding (and 
its consequences) remains an important iatro-
genic issue. Populations globally are also being 
treated increasingly with combinations of anti-
thrombotic therapies and medications such as 
nonsteroidal antiinflammatory drugs (NSAIDs), 
which can intensify such bleeding risks.5 Hence, 
further quantitative research, including valida-
tion of cause-specific bleeding scores associated 
with antithrombotic agents, is paramount to 
guide clinical management.
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To the Editor: The review article by Baron et al. 
does not address the clinical safety and efficacy 
of new antithrombotic agents in patients with 
cancer who are undergoing surgical procedures. 
A sizable number of patients with cancer under-
go surgery or procedures with local or regional 
anesthesia. Trials of oral direct thrombin inhibi-
tors and oral factor Xa inhibitors have enrolled 
less than 5% of patients with cancer.1 Because of 
a lack of data, the American Society of Clinical 
Oncology recommends against the use of new 
oral anticoagulants (for prevention and treatment) 
in patients with cancer.2 These patients also fre-
quently require anesthesia to undergo long inva-
sive procedures. The American Society of Re-
gional Anesthesia and Pain Medicine recommends 
cautious use of these agents in patients undergo-
ing neuraxial anesthesia.3 The lack of both effi-
cacy data and an antidote for reversibility of 
bleeding should prompt clinicians to be cautious 
while administering the new anticoagulants in 
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patients with cancer who are likely to undergo 
invasive procedures.
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To the Editor: The panel on the 2012 guide-
lines of the American College of Chest Physicians 
(ACCP) on periprocedural antithrombotic ther-
apy concluded that the quality of evidence for 
bridging therapy, even in patients with “high” 
thrombotic risk, was weak enough to warrant 
only grade 2C recommendations.1 This is the 
weakest recommendation possible and supports 
the suggested (not required) use of bridging ther-
apy in any patient group. Two ongoing placebo-
controlled trials (not one, as stated by Baron and 
colleagues) are investigating bridging therapy. 
These trials are Bridging Anticoagulation in Pa-
tients Who Require Temporary Interruption of 
Warfarin Therapy for an Elective Invasive Pro-
cedure or Surgery (ClinicalTrials.gov number, 
NCT00786474) and A Double Blind Randomized 
Control Trial of Post-Operative Low Molecular 
Weight Heparin Bridging Therapy Versus Placebo 
Bridging Therapy for Patients Who Are at High Risk 
for Arterial Thromboembolism (NCT00432796).
With respect to restarting therapy, most guide-
lines recommend restarting anticoagulation 
within 24 hours after a procedure involving a 
low risk of bleeding. Waiting 48 hours, as Baron 
et al. suggest, may expose a patient to the risk 
of thromboembolism. For procedures involving 
a high risk of bleeding, waiting 48 to 72 hours 
or considering a stepwise increase in antithrom-
botic therapy is suggested.2
Table 4 of the article by Baron et al. incor-
rectly recommends the use of anti–factor Xa 
“antibody” levels to monitor treatment with low-
molecular-weight heparin, rivaroxaban, and apix-
aban. Table 2 includes content from Table 1 in the 
2012 ACCP guidelines on periprocedural anti-
thrombotic agents and should cite this reference.1
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To the Editor: Baron et al. offer some very prac-
tical advice for treating patients who are receiv-
ing warfarin and who require bridging antico-
agulation therapy for procedures. Unfortunately, 
some of their advice could lead to undesirable 
outcomes. Patients with deficiencies in protein C, 
S, or both or dysproteinemia of either protein C or 
S require full therapeutic anticoagulation with hep-
arin (or a low-molecular-weight heparin) before 
initiation of warfarin; otherwise, they are at risk 
for the development of the prothrombotic state 
described as warfarin-induced skin necrosis.1,2 It 
is important to be aware of this when recom-
mending the postoperative timing of initiation of 
heparin (or a low-molecular-weight heparin) and 
warfarin.
Although typically it takes 5 to 7 days of war-
farin therapy to achieve anticoagulation, the half-
life of prothrombin is approximately 72 hours, 
and patients with an international normalized 
ratio (INR) of more than 1.9 do not receive anti-
coagulation therapy immediately. To avoid a pe-
riod of inadequate anticoagulation, the bridging 
heparin should not be discontinued when the 
INR is at a therapeutic level, but rather it should 
be continued at least 24 and preferably 48 hours 
after the INR is more than 1.9.
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To the Editor: The article by Baron et al. con-
tains some inconsistencies. The authors propose 
continuation of antithrombotic agents in patients 
undergoing cataract surgery and receiving intra-
ocular injections, since these procedures are con-
sidered to be associated with a low risk of bleed-
ing (<1.5%). Periorbital and vitreoretinal surgeries 
are classified as procedures associated with a 
high risk of bleeding (>1.5%) and, therefore, in 
patients who are at low risk for thrombotic 
events, anticoagulation therapy may be temporar-
ily discontinued without the use of bridging ther-
apy, whereas for selected high-risk patients, 
bridging therapy is strongly recommended (Table 
S1 in the Supplementary Appendix of the article, 
available at NEJM.org). However, this statement 
contradicts their proposal that procedures that 
can result in intraocular bleeding are associated 
with high risk and classified as major. Likewise, 
prospective cohort studies in cataract surgery 
have shown an incidence of clinically important 
bleeding of up to 3%.1 Peribulbar anesthesia2 and 
transconjunctival sutureless vitrectomies3 may be 
safe in these patients. Finally, one editorial has 
suggested that the risk of a cardiovascular event 
among patients in whom anticoagulant and anti-
platelet agents are discontinued is higher than 
the risk of bleeding during ocular surgery among 
patients who continue to receive these drugs.4
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The Authors Reply: In reply to the comments by 
Verma and Bhala: better predictors of bleeding 
are needed in patients receiving antithrombotic 
agents and NSAIDs, and data to support manage-
ment recommendations are lacking. The com-
ment regarding proton-pump inhibitors relates to 
spontaneous bleeding, which was not our focus.
With regard to the comments by Yusuf and 
Zalpour: we appreciate the citation to the Amer-
ican Society of Clinical Oncology recommenda-
tions and agree that treatment with a periproce-
dural antithrombotic agent is also important in 
patients undergoing neuraxial anesthesia.1
With regard to the comments by Spyropoulos 
and Ortel: the risk of periprocedural bleeding is 
triple that of the risk of thromboembolism; full-
dose parenteral anticoagulants administered for 
24 hours or less increase bleeding risk.2 There-
fore, we withhold full-dose parenteral anticoag-
ulants for 48 hours unless the risk of bleeding is 
low. Anti–factor Xa assays can be used for moni-
toring of anticoagulant effects.3 We apologize 
for not citing the ACCP guidelines (reference 2 of 
our article) in Table 2.
Bomzer describes the risk of warfarin-induced 
skin necrosis due to deficiencies in protein C, S, 
or both or dysproteinemia; however, this condi-
tion is rare. In the general population, the preva-
lence of this condition due to deficiency in pro-
tein C is 1 case per 200 to 500 persons, and the 
prevalence of this condition due to deficiency in 
protein S is 1 case per 800 persons. Heparin 
bridging during warfarin initiation appears to 
be warranted in these patients. However, univer-
sal bridging therapy for atrial fibrillation alone 
(estimated U.S. prevalence, 2.7 million to 6.1 mil-
lion cases) would greatly increase adverse events 
such as heparin-induced thrombocytopenia. New 
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anticoagulants may prevent warfarin-induced 
skin necrosis but cannot be recommended yet.
Finally, in reply to Grzybowski and Ascaso: 
the use of antithrombotic agents in ocular sur-
gery remains highly controversial. The stated 
bleeding rate of 3% is excessive in modern cata-
ract surgery. This avascular procedure, which is 
frequently performed with topical anesthesia, 
avoids potential retrobulbar hemorrhage due to 
retrobulbar anesthesia. However, retrobulbar an-
esthesia is frequently used in vitreoretinal sur-
gery. Catastrophic bleeding during vitreoretinal 
surgery can be due to choroidal hemorrhage and 
neovascularization in proliferative retinal diseas-
es. Bleeding after sutureless vitreoretinal surgery 
may be uncontrolled, since hypotonia in an open 
eye prevents tamponade.
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Case Reports of PML in Patients Treated for Psoriasis
To the Editor: In their letters about patients 
who were receiving oral dimethyl fumarate for 
the treatment of psoriasis, Ermis et al.1 and van 
Oosten et al.2 (April 25 issue) state that progres-
sive multifocal leukoencephalopathy (PML) had 
been diagnosed in two patients. Dimethyl fuma-
rate is the active ingredient in Fumaderm, which 
since 1994 has been registered for the treatment 
of psoriasis in Germany. Leukopenia and lym-
phopenia are known adverse effects of such 
therapy.
The summary of product characteristics for 
Fumaderm and current guidelines recommend 
that in all patients receiving the drug, a differ-
ential blood count should be obtained every 2 to 
3 months and the drug should be terminated if 
the leukocyte count is below 3000 per cubic mil-
limeter or the lymphocyte count is below 500 per 
cubic millimeter.3,4 In the safety database of the 
German drug agency (BfArM), which covers more 
than 180,000 patient-years of Fumaderm expo-
sure, no cases of PML have been documented in 
patients in whom these rules were applied. In 
contrast, in all cases of PML observed in asso-
ciation with therapy with dimethyl fumarate, 
physicians have not adequately treated lympho-
penia. The two patients who are described in the 
Journal both had lymphocyte counts below the 
threshold of 500 per cubic millimeter for more 
than 2 years. It appears, therefore, that these 
cases of PML occurred after long-standing, severe 
lymphopenia, which has been identified as a 
primary risk factor for PML.5
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